SELBELLE Tablets Launched by Eisai Medication that Improves Stomach Function by Protecting Gastric Mucosa from Stomach Acid
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today the launch of the stomach medication, SELBELLE tablets, which improves stomach symptoms such as heaviness, heartburn, and overeating by increasing active gastric mucus, and also by improving the delicate gastric functions.
In a healthy stomach, the 'stomach acid' that assists in food digestion, and 'gastric mucus' that protects the gastric mucosa from stomach acid are finely balanced. However, aging, poor physical condition, and irregular eating habits, among others, can disrupt this delicate balance resulting in a reduction in the amount of stomach mucus, and result in symptoms such as heaviness. Along with SELBELLE (granule formulation), SELBELLE tablets improves stomach symptoms such as repetitive heaviness, and heartburn with active ingredient 'Teprenone', which increases active gastric mucus and also protects gastric mucosa from stomach acid, and the other active ingredient that improves 'gastric peristalsis functions'. Meanwhile, SELBELLE series is the only over-the-counter drug that contains 'Teprenone'.
With the launch of SELBELLE tablets, another dosage form will be added to the present SELBELLE (granule formulation) that has already been launched. Taking the launch opportunity of the new formulation, Eisai will expand the gastrointestinal medicine market by using the new dimension, 'tablet', which relieves stomach discomfort and allows a return to normal balance.
As the middle-aged population increases in Japan, it is estimated that there will be a number of people who will suffer from a stomach discomfort resulting from a lack of gastric mucus. In addition to SELBELLE tablets in the SELBELLE product lineup series, Eisai also seeks to meet the benefits of those middle-aged persons suffering from stomach discomfort.
< Product Information >